Huang, H., Xu, Y., Guo, Z., Zhang, M., Li, W., Song, Y., Nie, J., Hu, W., Hei, T. K., & Zhou, G. (2025). Irradiation-responsive PRDM10-DT modulates the angiogenic response in human NSCLC cells in an SP1-dependent manner via the miR-663a/TGF-β1 axis. Journal of Translational Medicine, 23(1). https://doi.org/10.1186/s12967-025-06273-0

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301

Faiena, I., Adhikary, S., Schweitzer, C., Astrow, S. H., Grogan, T., Funt, S. A., Bot, A., Dorff, T., Rosenberg, J. E., Elashoff, D. A., Pantuck, A. J., & Drakaki, A. (2024). Gene and Protein Expression of MAGE and Associated Immune Landscape Elements in Non–Small-Cell Lung Carcinoma and Urothelial Carcinomas. Journal of Immunotherapy. https://doi.org/10.1097/cji.0000000000000538

Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices. (2024). Clinical Journal of Oncology Nursing. https://doi.org/10.1188/24.cjon.1-8.ap

Spira, A., Girard, N., Krebs, M., Park, K., Shu, C., Dougherty, L., & Cho, B. C. (2023). A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future Oncology, 19(33), 2213–2225. https://doi.org/10.2217/fon-2023-0284

Kinslow, C. J., ll, M. B., Cai, Y., Yan, J., Lorkiewicz, P. K., Al-Attar, A., Tan, J., Higashi, R. M., Lane, A. N., & Fan, T. W.-M. (2024). Stable isotope-resolved metabolomics analyses of metabolic phenotypes reveal variable glutamine metabolism in different patient-derived models of non-small cell lung cancer from a single patient. Metabolomics, 20(4). https://doi.org/10.1007/s11306-024-02126-x

Saqi, A., Liu, Y., Politis, M. G., Salvatore, M., & Jambawalikar, S. (2024). Combined expert-in-the-loop—random forest multiclass segmentation U-net based artificial intelligence model: evaluation of non-small cell lung cancer in fibrotic and non-fibrotic microenvironments. Journal of Translational Medicine, 22(1). https://doi.org/10.1186/s12967-024-05394-2

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Lin, C.-C., Garralda, E., Schöffski, P., Hong, D. S., Siu, L. L., Martin, M., Maur, M., Hui, R., Soo, R. A., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D. S., Cassier, P. A., Sarantopoulos, J., Weickhardt, A., Carvajal, R. D., Spratlin, J., … De Braud, F. (2023). A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2023.2290787

Altorki, N. K., Walsh, Z. H., Melms, J. C., Port, J. L., Lee, B. E., Nasar, A., Spinelli, C., Caprio, L., Rogava, M., Ho, P., Christos, P. J., Saxena, A., Elemento, O., Bhinder, B., Ager, C., Amin, A. D., Sanfilippo, N. J., Mittal, V., Borczuk, A. C., … McGraw, T. E. (2023). Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-44195-x

Kinslow, C. J., Wang, Y., Liu, Y., Zuev, K. M., Chaudhary, K. R., Wang, T. J. C., Donalek, C., Amori, M., & Cheng, S. K. (2023). Influenza activity and regional mortality for non-small cell lung cancer. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-47173-x

González-Ruíz, J., A.Baccarelli, A., Cantu-de-Leon, D., & Prada, D. (2023). Air Pollution and Lung Cancer: Contributions of Extracellular Vesicles as Pathogenic Mechanisms and Clinical Utility. Current Environmental Health Reports, 10(4), 478–489. https://doi.org/10.1007/s40572-023-00421-8

Dacic, S., Travis, W., Redman, M., Saqi, A., Cooper, W. A., Borczuk, A., Chung, J.-H., Glass, C., Lopez, J. M., Roden, A. C., Sholl, L., Weissferdt, A., Posadas, J., Walker, A., Zhu, H., Wijeratne, M. T., Connolly, C., Wynes, M., Bota-Rabassedas, N., … Wistuba, I. (2023). International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology, 18(10), 1290–1302. https://doi.org/10.1016/j.jtho.2023.07.017

Rusthoven, C. G., Staley, A. W., Gao, D., Yomo, S., Bernhardt, D., Wandrey, N., El Shafie, R., Kraemer, A., Padilla, O., Chiang, V., Faramand, A. M., Palmer, J. D., Zacharia, B. E., Wegner, R. E., Hattangadi-Gluth, J. A., Levy, A., Bernstein, K., Mathieu, D., Cagney, D. N., … Yamamoto, M. (2023). Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE). JNCI: Journal of the National Cancer Institute, 115(8), 926–936. https://doi.org/10.1093/jnci/djad073

Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., Hines, J., Aredo, J. V., Dennis, M. J., Chakrabarti, T., Scott, S. C., Bironzo, P., Scheffler, M., Christopoulos, P., Stenzinger, A., … Skoulidis, F. (2023). Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discovery, 13(7), 1556–1571. https://doi.org/10.1158/2159-8290.cd-22-1420

DeBlasi, J. M., Falzone, A., Caldwell, S., Prieto-Farigua, N., Prigge, J. R., Schmidt, E. E., Chio, I. I. C., Karreth, F. A., & DeNicola, G. M. (2023). Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression. Cancer Research, 83(12), 1953–1967. https://doi.org/10.1158/0008-5472.can-22-3848

Thummalapalli, R., Bernstein, E., Herzberg, B., Li, B. T., Iqbal, A., Preeshagul, I., Santini, F. C., Eng, J., Ladanyi, M., Yang, S.-R., Shen, R., Lito, P., Riely, G. J., Sabari, J. K., & Arbour, K. C. (2023). Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology, 7. https://doi.org/10.1200/po.23.00030

Dercle, L., Fronheiser, M., Rizvi, N. A., Hellmann, M. D., Maier, S., Hayes, W., Yang, H., Guo, P., Fojo, T., Schwartz, L. H., Zhao, B., & Leung, D. K. (2023). Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC. Journal of Thoracic Oncology, 18(5), 587–598. https://doi.org/10.1016/j.jtho.2022.12.019

Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., Griffin, A. T., Vokes, N. I., Sakhi, M., Kamesan, V., Rizvi, H., Ricciuti, B., Forde, P. M., Anagnostou, V., Riess, J. W., … Gainor, J. F. (2023). Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics, 55(5), 807–819. https://doi.org/10.1038/s41588-023-01355-5

Kim, D.-W., Kim, S.-W., Camidge, D. R., Shu, C. A., Marrone, K. A., Le, X., Blakely, C. M., Park, K., Chang, G.-C., Patel, S. P., Kar, G., Cooper, Z. A., Samadani, R., Pluta, M., Kumar, R., & Ramalingam, S. (2023). CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of Thoracic Oncology, 18(5), 650–656. https://doi.org/10.1016/j.jtho.2022.12.021

Pei, H., Dai, Y., Yu, Y., Tang, J., Cao, Z., Zhang, Y., Li, B., Nie, J., Hei, T. K., & Zhou, G. (2023). The Tumorigenic Effect of lncRNA AFAP1‐AS1 is Mediated by Translated Peptide ATMLP Under the Control of m6A Methylation. Advanced Science, 10(13). Portico. https://doi.org/10.1002/advs.202300314

Park, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2023). Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer, 178, 166–171. https://doi.org/10.1016/j.lungcan.2023.02.008

Lee, S. M., Fan, W., Wang, A., Vaidya, R., Redman, M. W., Gettinger, S. N., Bazhenova, L., Herbst, R. S., Hershman, D. L., & Unger, J. M. (2023). Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). JCO Clinical Cancer Informatics, 7. https://doi.org/10.1200/cci.22.00165

Steinfort, D. P., Antippa, P., Rangamuwa, K., Irving, L. B., Christie, M., Chan, E., Marinelli, B., Wang, J., Yoneda, K. Y., Raina, S., & Herth, F. J. (2023). Safety and Feasibility of a Novel Externally Cooled Bronchoscopic Radiofrequency Ablation Catheter for Ablation of Peripheral Lung Tumours: A First-In-Human Dose Escalation Study. Respiration, 102(3), 211–219. Portico. https://doi.org/10.1159/000529167

Maniar, R., Gallitano, S. M., Husain, S., Moazami, G., Weiss, M. J., & Shu, C. A. (2023). Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition. Journal of the National Comprehensive Cancer Network, 21(3), 232–234. https://doi.org/10.6004/jnccn.2022.7084

Maniar, R., Wang, P. H., Washburn, R. S., Kratchmarov, R., Coley, S. M., Saqi, A., Pan, S. S., Hu, J., Shu, C. A., Rizvi, N. A., Henick, B. S., & Reiner, S. L. (2022). Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy. Cancer Immunology Research, 11(2), 164–170. https://doi.org/10.1158/2326-6066.cir-22-0524

Pan, Y., Han, H., Hu, H., Wang, H., Song, Y., Hao, Y., Tong, X., Patel, A. S., Misirlioglu, S., Tang, S., Huang, H.-Y., Geng, K., Chen, T., Karatza, A., Sherman, F., Labbe, K. E., Yang, F., Chafitz, A., Peng, C., … Wong, K.-K. (2023). KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer Cell, 41(1), 88-105.e8. https://doi.org/10.1016/j.ccell.2022.11.015

Savari, O., Febres‐Aldana, C., Chang, J. C., Fanaroff, R. E., Ventura, K., Bodd, F., Paik, P., Vundavalli, M., Saqi, A., Askin, F. B., Travis, W. D., & Rekhtman, N. (2022). Non‐small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours. Histopathology, 82(2), 242–253. Portico. https://doi.org/10.1111/his.14801

de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., Cheng, Y., Moiseyenko, V., Summers, Y., Vynnychenko, I., Lee, S. Y., Bryl, M., Zer, A., Erman, M., Timcheva, C., Raja, R., Naicker, K., Scheuring, U., Walker, J., … Mok, T. (2023). NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106–119. https://doi.org/10.1016/j.jtho.2022.09.223

Capaccione, K. M., Huang, S., D’souza, B., Leb, J., Luk, L., Goldstein, J., May, B., Deng, A., & Salvatore, M. M. (2023). Radiographic features of pneumonitis in patients treated with immunotherapy compared to traditional chemotherapy for non-small cell lung cancer. Clinical Imaging, 93, 106–112. https://doi.org/10.1016/j.clinimag.2022.03.006

Primakov, S. P., Ibrahim, A., van Timmeren, J. E., Wu, G., Keek, S. A., Beuque, M., Granzier, R. W. Y., Lavrova, E., Scrivener, M., Sanduleanu, S., Kayan, E., Halilaj, I., Lenaers, A., Wu, J., Monshouwer, R., Geets, X., Gietema, H. A., Hendriks, L. E. L., Morin, O., … Lambin, P. (2022). Automated detection and segmentation of non-small cell lung cancer computed tomography images. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-30841-3

Chaudhary, K. R., Kinslow, C. J., Cheng, H., Silva, J. M., Yu, J., Wang, Tony. J., Hei, T. K., Halmos, B., & Cheng, S. K. (2022). Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-14448-8

Van Egeren, D., Kohli, K., Warner, J. L., Bedard, P. L., Riely, G., Lepisto, E., Schrag, D., LeNoue-Newton, M., Catalano, P., Kehl, K. L., Michor, F., Fiandalo, M., Foti, M., Khotskaya, Y., Lee, J., Peters, N., Sweeney, S., Abraham, J., … Walther, Z. (2022). Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-21448-1

Ricciuti, B., Wang, X., Alessi, J. V., Rizvi, H., Mahadevan, N. R., Li, Y. Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., Vokes, N. I., Recondo, G., Lamberti, G., Lawrence, M., Vaz, V. R., Leonardi, G. C., Plodkowski, A. J., Gupta, H., Cherniack, A. D., … Awad, M. M. (2022). Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncology, 8(8), 1160. https://doi.org/10.1001/jamaoncol.2022.1981

Bailey, S., Wang, Q., Kong, C. Y., Stone, K., Veluswamy, R., Bates, S. E., Smith, C. B., Wisnivesky, J. P., & Sigel, K. (2022). Optimizing the use of adjuvant chemotherapy in non-small cell lung cancer patients with comorbidities. Current Problems in Cancer, 46(4), 100867. https://doi.org/10.1016/j.currproblcancer.2022.100867

Henick, B. S., Villarroel-Espindola, F., Datar, I., Sanmamed, M. F., Yu, J., Desai, S., Li, A., Aguirre-Ducler, A., Syrigos, K., Rimm, D. L., Chen, L., Herbst, R. S., & Schalper, K. A. (2022). Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 10(7), e005025. https://doi.org/10.1136/jitc-2022-005025

Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M., Dubinett, S. M., Ferris, A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., Hellmann, M. D., Hirsch, F. R., Johnson, M. L., Malik, S., Morgensztern, D., Neal, J. W., Patel, J. D., Rimm, D. L., Sagorsky, S., … Herbst, R. S. (2022). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal for ImmunoTherapy of Cancer, 10(5), e003956. https://doi.org/10.1136/jitc-2021-003956

Biswas, A. K., Han, S., Tai, Y., Ma, W., Coker, C., Quinn, S. A., Shakri, A. R., Zhong, T. J., Scholze, H., Lagos, G. G., Mela, A., Manova-Todorova, K., de Stanchina, E., Ferrando, A. A., Mendelsohn, C., Canoll, P., Yu, H. A., Paik, P. K., Saqi, A., … Acharyya, S. (2022). Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse inEGFR-Mutant Lung Cancer. Cancer Discovery, 12(4), 1002–1021. https://doi.org/10.1158/2159-8290.cd-21-0910

Wang, F., Liu, Y., Qiu, W., Shum, E., Feng, M., Zhao, D., Zheng, D., Borczuk, A., Cheng, H., & Halmos, B. (2022). Functional Analysis of MET Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination. Cancer Research, 82(7), 1365–1379. https://doi.org/10.1158/0008-5472.can-21-1327